ArticlePhysiological research2026
Hydrogen Sulfide Suppresses RANKL-Induced Osteoclast Differentiation by Modulating Nrf2/GPX4 Signaling.
Article in Physiological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excessive osteoclast activity drives bone-resorptive disorders, and oxidative stress is a key regulator of osteoclast differentiation. Hydrogen sulfide (H?S), an endogenous antioxidant, may modulate this process, but its mechanisms remain unclear. In this study, RANKL (50 ng/mL) was used to induce osteoclastogenesis in RAW264.7 cells, with or without the H?S donor sodium hydrosulfide (NaHS; 50-200 ?M). Osteoclast formation was evaluated by TRAP staining and NFATc1/Cathepsin K expression, while oxidative stress, lipid peroxidation, mitochondrial function, and ferroptosis-related parameters were assessed. Mechanistic studies revealed that NaHS promoted Nrf2 nuclear translocation and upregulated GPX4, HO-1, and NQO1, whereas inhibition of Nrf2 or GPX4 partially reversed these effects. NaHS significantly suppressed osteoclast differentiation, alleviated oxidative stress, and restored mitochondrial function. These findings demonstrate that H?S inhibits RANKL-induced osteoclastogenesis via the Nrf2/GPX4 pathway and suggest this redox axis as a potential therapeutic target for bone-resorptive diseases.
Indexed as
Identifiers
42708873PMC13580674What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.